Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer " primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer. Its vaccine technologies focus on immunizing against retired proteins that found to be expressed in certain forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
| 3.05 | |
| 2.87 | |
| - | |
| 3.12 | |
| 2.87 | |
| 2.145-5.13 | |
| 92 499 K | |
| 32 007 K | |
| 0 | |
| -0.1 | |
| 0.894 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Some of the most explosive opportunities can be found in biotech stocks. Look at CRISPR Therapeutics (NASDAQ:CRSP), for example. Leading up to U.S. FDA rulings, the stock exploded from a low of abou...
SAN JOSE, Calif., Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today anno...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
